A renal biopsy–anchored multi-marker signature involving AOPEP SNP-driven splicing, miR-27b-3p and glycated albumin for stratifying renal damage in type 2 diabetes
An erratum to this article was published (Diabetes Res Clin Pract, Mar 2026 ↗)
Authors' conclusion
We identify a genotype- and glucose-dependent mechanism regulating miR-27b-3p via AOPEP splicing and propose a biopsy-anchored, non-invasive biomarker panel (rs10761364, GA, miR-27b-3p) to differentiate DN from NDRD, supporting personalized nephrology care.
Study context
- Population
- Biopsy-verified chronic kidney disease (CKD) patients with and without T2D
- Participants
- 231 patients
- Comparison
- Diabetic nephropathy (DN) vs non-diabetic renal disease (NDRD)
- Outcome
- Discrimination of DN from NDRD
Methodological detailsbiopsy-verified cohort, mechanistic in vitro component
- Biopsy-verified cohort
- Mechanistic in vitro component
Performance
As reported in the abstract
AUC of model combining rs10761364, glycated albumin (GA) and urinary miR-27b-3p (up to)
0.93
Further findings
- miR-27b-3p inversely correlated with GA
- GA-based models outperformed those using HbA1c
Original publication
A renal biopsy–anchored multi-marker signature involving AOPEP SNP-driven splicing, miR-27b-3p and glycated albumin for stratifying renal damage in type 2 diabetes. Diabetes Res Clin Pract. Published 9 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →